Invivyd, Inc. (NASDAQ:IVVD) Shares Acquired by JPMorgan Chase & Co.

JPMorgan Chase & Co. boosted its position in Invivyd, Inc. (NASDAQ:IVVD) by 644.1% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 256,900 shares of the company’s stock after buying an additional 222,375 shares during the quarter. JPMorgan Chase & Co. owned 0.21% of Invivyd worth $114,000 at the end of the most recent quarter.

Separately, Barclays PLC increased its position in shares of Invivyd by 179.6% during the third quarter. Barclays PLC now owns 117,973 shares of the company’s stock worth $120,000 after acquiring an additional 75,780 shares during the last quarter. 70.36% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

IVVD has been the subject of a number of analyst reports. HC Wainwright reissued a “buy” rating and issued a $10.00 price target on shares of Invivyd in a report on Wednesday, March 26th. D. Boral Capital reiterated a “buy” rating and set a $9.00 target price on shares of Invivyd in a research note on Thursday, March 20th.

Invivyd Stock Performance

Shares of Invivyd stock opened at $0.58 on Tuesday. Invivyd, Inc. has a 1 year low of $0.35 and a 1 year high of $2.74. The firm’s 50-day simple moving average is $0.69 and its 200-day simple moving average is $0.77. The firm has a market cap of $69.03 million, a PE ratio of -0.29 and a beta of 0.40.

Invivyd (NASDAQ:IVVD) last announced its quarterly earnings data on Thursday, March 20th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.25) by $0.10. The firm had revenue of $13.80 million for the quarter, compared to analyst estimates of $13.57 million. On average, equities analysts predict that Invivyd, Inc. will post -1.64 earnings per share for the current year.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.